Aarti Pharmalabs Limited

Aarti Pharmalabs Limited

1,015.00
INR
+28.75
(+2.92%)
28.29EPS
33.64P/E
86.35BMarket Cap
Feb 10Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
131.53
213.63
200.33
230.16
197.23
238.35
Basic EPS, GAAP
- -
13.49
21.35
23.93
30.06
19.27
28.31
Free Cash Flow per Basic Share
- -
-20.4
14.4
1.94
-12.55
-20.56
- -
Dividend per Share
- -
- -
2
2
3.5
4
- -
Book Value per Share
0.03
152.99
171.97
193.88
219.55
234.35
248.65
Tangible Book Value per Share
0.03
150.32
167.38
185.38
208.49
220.69
233.38
Basic Weighted Avg Shares
91
91
91
91
91
91
91
Sales/Revenue/Turnover
- -
11,920
19,360
18,155
20,860
17,878
21,612
Operating Margin (%)
- -
13.86
14.44
17.23
18.1
16.67
17.69
Depreciation Expense
- -
421
625
732
869
1,043
1,173
Net Income, GAAP
- -
1,223
1,935
2,169
2,724
1,747
2,567
Effective Tax Rate (%)
- -
21.32
25.8
27.82
24.48
24.99
24.63
Profit Margin (%)
- -
10.26
9.99
11.95
13.06
9.77
11.88
Working Capital
2
4,475
5,624
6,513
6,651
4,597
4,773
LT Debt
- -
21
7
167
1,229
2,530
2,033
Total Equity
2
13,865
15,585
17,570
19,899
21,246
22,548
Return on Invested Capital (%)
- -
14.98
11.81
11.84
12.82
8.36
9.71
Return on Capital (%)
- -
14.18
11.94
12.02
13.15
7.91
10.24
Return on Common Equity (%)
- -
17.63
13.14
13.08
14.54
8.49
11.94

Capital Structure

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
5,164
- -
6,938
LT Borrowings
2,008
- -
1,598
LT Finance Leases
522
- -
435
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
91
91
Market Capitalization
53,420
61,649
86,350

Working Capital

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
13,973
- -
16,565
Cash, Cash Equivalents & STI
89
- -
235
Accounts Receivable, Net
5,833
- -
6,850
Inventories
6,403
- -
7,942
Total Current Liabilities
9,376
- -
11,792
Payables & Accruals
- -
- -
- -
ST Debt
5,164
- -
6,938
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
121,556.57%
6.77%
Free Cash Flow
- -
- -
63.87%
Net Income, GAAP
- -
-531,534.5%
-35.86%
Sales/Revenue/Turnover
- -
- -
-14.3%
Total Cash Common Dividend
- -
- -
14.31%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,555
4,580
5,378
5,638
20,860
2026
3,862
4,183
4,323
5,826
17,878
2027
5,358
6,105
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6.12
6.03
8.16
9.75
30.06
2026
5.08
2.26
5.29
6.74
19.27
2027
8.4
7.88
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3.5
2026
- -
- -
- -
- -
4
2027
- -
- -
- -
- -
- -

Company Description

CEO
Hetal Gala
Full Time Employees
4,218
Sector
Health technology
Industry
Pharmaceuticals: major
Address
204, Udyog Kshetra Mumbai MH India 400080
IPO Date
Jan 30, 2023
Business
Aarti Pharmalabs Limited is a key developer and manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, novel chemical entities, and xanthine derivatives. The company also extends comprehensive contract development and manufacturing organization (CDMO) services for drug substances and new chemical entities to global innovator and biotech firms. With a robust presence across India, its facilities produce a diverse range of generic APIs catering to cardiovascular, anti-diabetic, anti-cancer, and central nervous system therapeutic areas, alongside high-potency APIs. Aarti Pharmalabs holds a significant position as a leading Indian producer of xanthine derivatives, including caffeine, serving the pharmaceutical, nutraceutical, and beverage sectors worldwide, with exports reaching regulated markets such as the US, European Union, and Japan. Formed in November 2019, the company previously operated as Aarti Organics Limited and was later demerged from Aarti Industries Limited in October 2022 to become an independently listed entity.